Dose response to interferon therapy in multiple sclerosis: An evaluation of the evidence

Current Medical Research and Opinion

Volumn 25, Issue 3, 2009, Pages 547-557

  Freedman, S Mitchell ^a  

^a Raleigh Neurology Associates   (United States)

Author keywords

Dose response relationship; Interferon; Multiple sclerosis; Review

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; CORTICOSTEROID; INTERFERON BETA SERINE; PLACEBO;

CLINICAL TRIAL; DATA BASE; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; EMBASE; EVIDENCE BASED PRACTICE; FATIGUE; FEVER; FLU LIKE SYNDROME; HUMAN; INJECTION SITE ERYTHEMA; INJECTION SITE REACTION; LABORATORY; LEUKOPENIA; LOW DRUG DOSE; LYMPHOCYTOPENIA; MEDLINE; MULTIPLE SCLEROSIS; MUSCLE WEAKNESS; NEUTROPENIA; PROSPECTIVE STUDY; RELAPSE; REVIEW; SIDE EFFECT; SKIN NECROSIS; SYSTEMATIC REVIEW;

EID: 66149130823     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990802677787     Document Type: Review

References (57)

1. Agency for Healthcare Research and Quality. Making Health Care Safer: A Critical Analysis of Patient Safety Practices. Evidence Report/Technology Assessment No. 43. AHRQ Publication No. 01-E058, July 2001. Rockville, MD, USA: Agency for Healthcare Research and Quality. Available at: http://www.ahrq.gov/ clinic/ptsafety/. Accessed July 16, 2008
2. IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-661
3. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-294 (Pubitemid 26100751)
4. PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/ remitting multiple sclerosis. Lancet 1998;352:1498-1504 (Pubitemid 28512925)
5. Galetta SL, Markowitz C, Lee AG. Immunomodulatory agents for the treatment of relapsing multiple sclerosis. A systematic review. Arch Intern Med 2002;162:2161-2169
6. Paty DW, Li DK. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind placebo-controlled trial. Neurology 1993;43:662-667
7. Li DK, Paty DW. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-β1a in relapsing-remitting multiple sclerosis. Ann Neurol 1999;46:197-206 (Pubitemid 29382876)
8. Simon J, Jacobs LD, Campion M, et al., for the Multiple Sclerosis Collaborative Research Group. Magnetic resonance studies of intramuscular interferon β-1a for relapsing multiple sclerosis. Ann Neurol 1997;43:79-87
9. Clanet M, Radue EW, Kappos L, et al. A randomized double-blind dose-comparison study of weekly interferon β-1a in relapsing MS. Neurology 2002;59:1507-1517 (Pubitemid 35387054)
10. Once Weekly Interferon for MS Study Group. Evidence of interferon β-1a dose response in relapsing-remitting MS. The OWIMS study. Neurology 1999;53:679-686
11. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000; 343:898-904 (Pubitemid 30727801)
12. Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001;357:1576-1582 (Pubitemid 32488815)
13. Kappos L, Polman CH, Freedman SM, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006;67:1242-1249 (Pubitemid 44563835)
14. Rebif® (interferon beta-1a) [package insert]. Geneva, Switzerland: Ares-Serono, Inc.; 2007
15. Goldstein D, Sielaff KM, Storer BE, et al. Human biologic response modification by interferon in the absence of measurable serum concentrations: a comparative trial of subcutaneous and intravenous interferon-β serine. J Natl Cancer Inst 1989;81:1061-1068 (Pubitemid 19175140)
16. ser and gamma in humans. J Clin Invest 1990;86:1211-1221
17. Johnson KP, Knobler RL, Greenstein JI, et al. Recombinant human beta interferon treatment of relapsing-remitting multiple sclerosis: pilot study results [abstract]. Neurology 1990;40 (Suppl 1):261
18. Alam J, McAllister A, Scaramucci J, et al. Pharmacokinetics and pharmacodynamics of interferon beta-1a (IFNβ-1a) in healthy volunteers after intravenous, subcutaneous, or intramuscular administration. Clin Drug Investig 1997;14:35-43 (Pubitemid 27338835)
19. Salmon P, Cotonnec J-YL, Galazka A, et al. Pharmacokinetics and pharmacodynamics of recombinant human interferon-β in healthy male volunteers. J Interferon Cytokine Res 1996;16: 759-764 (Pubitemid 26389112)
20. Munafo A, Trinchard-Lugan I, Nguyen TX, et al. Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon beta-1a after intramuscular and subcutaneous administration. Eur J Neurol 1998;5:187-193 (Pubitemid 28142571)
21. Stürzebecher S, Maibauer R, Heuner A, et al. Pharmacodynamic comparison of single doses of IFN-β1a and IFN-β1b in healthy volunteers. J Interferon Cytokine Res 1999;19:1257-1264
22. Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon β-1a treatment regimens in MS. The EVIDENCE Trial. Neurology 2002;59:1496-1506
23. Durelli L, Verdun E, Barbero P, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002;359:1453-1460 (Pubitemid 34457761)
24. Avonex® (interferon beta-1a) [package insert]. Cambridge, MA: Biogen Idec, Inc.; 2007
25. Betaseron® (interferon beta-1b) [package insert]. Richmond, CA: Berlex Laboratories; 2007
26. Frohman E, Phillips T, Kokel K, et al. Disease-modifying therapy in multiple sclerosis: strategies for optimizing management. Neurologist 2002;8:227-236 (Pubitemid 34810404)
27. Rossman HS. Neutralizing antibodies to multiple sclerosis treatments. J Manag Care Pharm 2004;10:S12-8
28. Bertolotto A, Malucchi S, Sala A, et al. Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory. J Neurol Neurosurg Psychiatry 2002;73: 148-153 (Pubitemid 34824267)
29. Sorensen PS, Koch-Henriksen N, Ross C, et al., and the Danish Multiple Sclerosis Study Group. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology 2005;65:33-39
30. The IFNB Multiple Sclerosis Study Group andthe University of British Columbia MS/MRI Analysis Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 1996;47:889-894
31. The PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group and the University of British Columbia MS/MRI Analysis GroupPRISMS-4: long-term efficacy of interferon-β- 1a in relapsing MS. Neurology 2001;56:1628-1636
32. Kappos L, Clanet M, Sandberg-Wollheim M, et al. Neutralizing antibodies and efficacy of interferon β-1a. A 4-year controlled study. Neurology 2005;65:40-47
33. Francis GS, Rice GP, Alsop JC, for the PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group. Interferon b-1a in MS. Results following development of neutralizing antibodies in PRISMS. Neurology 2005;65:48-55
34. Dupont SA, Goelz S, Goyal J, et al. Mechanisms for regulation of cellular responsiveness to human IFNβ-1a. J Interferon Cytokine Res 2002;22:491-501 (Pubitemid 34579552)
35. Yasukawa H, Sasaki A, Yoshimura A. Negative regulation of cytokine signaling pathways. Annu Rev Immunol 2000;18: 143-164 (Pubitemid 30365377)
36. Panitch H, Goodin D, Francis G, et al. Benefits of high dose, high frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: Final comparative results of the EVIDENCE trial. J Neurol Sci 2005;239:67-74 (Pubitemid 41617417)
37. US Food and Drug Administration Supplemental Biologics License Application. Evidence of Interferon Dose Response: European North American Comparative Efficacy (EVIDENCE) Study SBLA no. 103780/5010 April 16, 2003
38. Schwid SR, Thorpe J, Sharief M, et al. Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis. The EVIDENCE Study. Arch Neurol 2005; 62:785-792 (Pubitemid 40656095)
39. Goodin DS, Frohman EM, Garmany GP Jr, et al. Disease modifying therapies in multiple sclerosis. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002;58:169-178
40. Rice GP, Incorvaia B, Munari L, et al., Interferon in relapsing-remitting multiple sclerosis. In: The Cochran Library. Issue 3. Chichester, UK: John Wiley & Sons, Ltd.; 2004
41. Knobler RL, Greenstein JI, Johnson KP, et al. Systemic recombinant human interferon-β treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up. J Interferon Res 1993;13:333-340 (Pubitemid 24353056)
42. Durelli L, Bongioanni MR, Cavallo R, et al. Chronic systemic high-dose recombinant interferon alfa-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis. Neurology 1994;44:406-413
43. Myhr KM, Riise T, Green Lilleas FE, et al. Interferon-α2a reduces MRI disease activity in relapsing-remitting multiple sclerosis. Norwegian Study Group on Interferon-alpha in Multiple Sclerosis. Neurology 1999;52:1049-1056 (Pubitemid 29161618)
44. Clanet M. Interferon-beta in the treatment of multiple sclerosis. Do clinical data support the existence of a ceiling effect? Clin Drug Investig 2001;21:307-318
45. Freedman MS, Francis GS, Sanders EA, et al. Randomized study of once-weekly interferon β-1a therapy in relapsing multiple sclerosis: three-year data from the OWIMS study. Mult Scler 2005;11:41-45 (Pubitemid 40259973)
46. Interferon beta-1a Summary Basis for Approval. US Food and Drug Administration Biologics License Application 103628; 1996
47. Barbero P, Verdun E, Bergui M, et al. High-dose, frequently administered interferon beta therapy for relapsing-remitting multiple sclerosis must be maintained over the long term: the interferon beta dose-reduction study. J Neurol Sci 2004; 222:13-19 (Pubitemid 38881501)
48. Milanese C, La Mantia L, Palumbo R, et al. A post-marketing study on interferon β 1b and 1a treatment in relapsing-remitting multiple sclerosis: different response in drop-outs and treated patients. J Neurol Neurosurg Psychiatry 2003;74:1689-1692 (Pubitemid 37542062)
49. Trojano M, Liguori M, Paolicelli D, et al. Interferon beta in relapsing-remitting multiple sclerosis: an independent postmarketing study in southern Italy. Mult Scler 2003;9:451-457 (Pubitemid 37287722)
50. Rio J, Tintore M, Nos C, et al. Interferon beta in relapsing-remitting multiple sclerosis. An eight years experience in a specialist multiple sclerosis centre. J Neurol 2005;252:795-800 (Pubitemid 40984854)
51. Seijo-Martinez M, Amigo MC, Arias M, et al. Experience of interferon beta (IFN-b) treatment in relapsing-remitting (RR) and secondary progressive (SP) multiple sclerosis (MS) in Galicia (Spain) [abstract]. Mult Scler 2001;7(Suppl 1):S54
52. Haas J, Firzlaff M. Twenty-four-month comparison of immunomodulatory treatments - a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone®). Eur J Neurol 2005;12:425-431 (Pubitemid 40768660)
53. Limmroth V, Malessa R, Zettl UK, et al., for the QUASIMS Study Group. Quality Assessment in Multiple Sclerosis Therapy (QUASIMS). A comparison of interferon beta therapies for relapsing-remitting multiple sclerosis. J Neurol 2007; 254:67-77 (Pubitemid 46295070)
54. Koch-Henriksen N, Sorensen PS, Christensen T, et al., for the Danish Multiple Sclerosis Group. A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis. Neurology 2006;66:1-5
55. Patti F, Pappalardo A, Florio C, et al. Effects of interferon beta-1a and -1b over time: 6-year results of an observational head-to-head study. Acta Neurol Scand 2006;113:241-247 (Pubitemid 43382597)
56. Hauser SL, Dawson DM, Lehrich JR, et al. Intensive immunosuppression in progressive multiple sclerosis; a randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med 1983;308:173-180 (Pubitemid 13171135)
57. Barnes D, Hughes RAC, Morris RW, et al. Randomized trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis. Lancet 1997;349:902-906 (Pubitemid 27139818)